HopeStage
Back to all studies
CompletedNCT05895643

Semaglutide and alcohol use with co-occurring obesity

About this title

Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?

Read the official source — NCT05895643
Medication studyAges 18–70DenmarkAddiction
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 70 years.

Listed locations
FrederiksbergSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: June 13, 2023
Recruitment status
Completed
Enrollment listed in the registry
108
Sponsor
Psychiatric Centre Rigshospitalet
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Denmark
Age range
From 18 Years to 70 Years
Official registry ID
NCT05895643
Official title
Show the full official title

Does the Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Frederiksberg

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Psychiatric Centre Rigshospitalet.

Did this study involve medication?

Yes. The study involved medication, including Semaglutide Injectable Product and Placebo.

Who was this study for?

Listed age limits: 18 years to 70 years.

Want to explore more studies?

Explore studies